Glaukos Establishes Direct Sales Organization and Launches iStent inject® Trabecular Micro-Bypass Stent in Australia
LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, today announced that it has established a direct sales organization and launched the iStent inject® Trabecular Micro-Bypass Stent in Australia. The iStent inject is approved by the Australian Therapeutics Goods Administration for use in conjunctio
